American Journal Of Cardiovascular Drugs SCIE

国际简称：AM J CARDIOVASC DRUG 参考译名：美国心血管药物杂志

主要研究方向：医学-心血管系统非预警期刊审稿周期： 12周，或约稿

《美国心血管药物杂志》(American Journal Of Cardiovascular Drugs)是一本由Springer International Publishing出版的以医学-心血管系统为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

4区中科院分区
Q2 JCR分区
56 年发文量
2.8 IF影响因子
未开放 是否OA
46 H-index
2001 创刊年份
Bimonthly 出版周期
English 出版语言

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.

Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.

The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

[ 查看全部 ]

投稿咨询加急咨询

American Journal Of Cardiovascular Drugs期刊信息

ISSN：1175-3277
出版语言：English
是否OA：未开放
E-ISSN：1179-187X
出版地区：NEW ZEALAND
是否预警：否
出版商：Springer International Publishing
出版周期：Bimonthly
创刊时间：2001
开源占比：0.2011
Gold OA文章占比：29.66%
OA被引用占比：0.2597...
出版国人文章占比：0.12
出版撤稿占比：0
研究类文章占比：51.79%

American Journal Of Cardiovascular Drugs CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

6.7

0.79

0.784

学科类别	分区	排名	百分位
大类：Medicine 小类：Cardiology and Cardiovascular Medicine	Q1	74 / 387	81%
大类：Medicine 小类：Pharmacology (medical)	Q1	63 / 272	77%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

American Journal Of Cardiovascular Drugs中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统 PHARMACOLOGY & PHARMACY 药学	4区 4区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统 PHARMACOLOGY & PHARMACY 药学	3区 3区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	PHARMACOLOGY & PHARMACY 药学 CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统	3区 4区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统 PHARMACOLOGY & PHARMACY 药学	4区 3区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	PHARMACOLOGY & PHARMACY 药学 CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统	3区 4区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统 PHARMACOLOGY & PHARMACY 药学	4区 4区

American Journal Of Cardiovascular Drugs JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：CARDIAC & CARDIOVASCULAR SYSTEMS	SCIE	Q2	79 / 220	64.3%
学科：PHARMACOLOGY & PHARMACY	SCIE	Q2	158 / 354	55.5%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：CARDIAC & CARDIOVASCULAR SYSTEMS	SCIE	Q2	84 / 220	62.05%
学科：PHARMACOLOGY & PHARMACY	SCIE	Q2	163 / 354	54.1%

American Journal Of Cardiovascular Drugs历年数据统计

影响因子

中科院分区

American Journal Of Cardiovascular Drugs中国学者发文选摘

1、Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China
Author: Lou, Yake; Hu, Tianyang; Huang, Jing

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 47-57. DOI: 10.1007/s40256-022-00550-9
2、Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry
Author: Millesimo, Michele; Elia, Edoardo; Marengo, Giorgio; De Filippo, Ovidio; Raposeiras-Roubin, Sergio; Wanha, Wojciech; Abu-Assi, Emad; Kinnaird, Tim; Ariza-Sole, Albert; Liebetrau, Christoph; Manzano-Fernandez, Sergio; Iannaccone, Mario; Henriques, Jose Paulo Simao; Templin, Christian; Wilton, Stephen B.; Velicki, Lazar; Xanthopoulou, Ioanna; Correia, Luis; Cerrato, Enrico; Rognoni, Andrea; Nunez-Gil, Ivan; Song, Xiantao; Kawaji, Tetsuma; Quadri, Giorgio; Huczek, Zenon; Paz, Rafael Cobas; Juanatey, Jose Ramon Gonzalez; Nie, Shao-Ping; Kawashiri, Masa-Aki; Dominguez-Rodriguez, Alberto; Conrotto, Federico; D'Ascenzo, Fabrizio; De Ferrari, Gaetano Maria

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 77-87. DOI: 10.1007/s40256-022-00554-5
3、Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial
Author: Zhou, Qiang; Wang, Zhiqiang; Wang, Heming; Chen, Zhidong; Li, Xiaoyi; Dai, Xiangrong; Zhang, Yong; Yu, Xiaohui; Zhou, Renpeng; Hu, Wei

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 101-112. DOI: 10.1007/s40256-022-00562-5
4、Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity
Author: Feng, Jie; Wu, Yanqing

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 231-246. DOI: 10.1007/s40256-023-00573-w
5、Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis
Author: Zheng, Nan; Zhong, Jinyan; Chen, Xi; Su, Jia; Liu, Chengjiang; Jiang, Longfu

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 257-267. DOI: 10.1007/s40256-023-00574-9
6、Characteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021
Author: Hao, Jun; Li, Chen; Li, Junrong; Wang, Chuangshi; Li, Yang; He, Chen; Liu, Weida; Li, Sidong; Zuo, Ling; Hui, Wen

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 301-310. DOI: 10.1007/s40256-023-00575-8
7、Effects of Rosuvastatin and Aspirin on Retinal Vascular Structures in Hypercholesterolemic Patients with Low-to-Moderate Risk of Coronary Artery Disease
Author: Li Li, Shuang Wang, Huilian Huang, Yi Cai, Yutao Xi, Ying Bai, Changsheng Ma

Journal: American Journal of Cardiovascular Drugs, 2019, Vol., , DOI:10.1007/s40256-019-00330-y
8、The Efficacy and Safety of Aerosolized Iloprost in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
Author: Hongyu Kuang, Qiang Li, Qijian Yi, Tiewei Lu

Journal: American Journal of Cardiovascular Drugs, 2019, Vol., , DOI:10.1007/s40256-018-00324-2